Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management

Johann Wolfgang Goethe University Hospital

Overview

The optimal valve substitute for patients between 60-70 years is controversial. We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.

Study Type

OBSERVATIONAL

Conditions

Anticoagulation Mechanical Heart Valve Replacement

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * heart valve replacement Exclusion Criteria: * CABG * Afib

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.